Imatinib: a targeted clinical drug development.

Abstract:

:Imatinib (Gleevec) (formerly STI571) is an orally bioavailable rationally developed inhibitor of the tyrosine kinases Bcr-Abl, Kit, and platelet-derived growth factor receptor (PDGFR). In 4 years of clinical development, more than 12,000 patients have been treated in the clinical development program. Imatinib was first shown to be highly effective in the treatment of all stages of chronic myelogenous leukemia (CML). Moreover, preliminary results of a randomized study have demonstrated superior efficacy and safety of first-line imatinib therapy compared with a combination of interferon and cytarabine. Imatinib has also been shown to be the only effective drug therapy in the treatment of patients with metastatic gastrointestinal stromal tumors expressing the stem cell factor (SCF) receptor Kit. This review outlines the successive steps in the clinical development of this new, targeted anticancer agent.

journal_name

Semin Hematol

journal_title

Seminars in hematology

authors

Capdeville R,Silberman S

doi

10.1053/shem.2003.50037

subject

Has Abstract

pub_date

2003-04-01 00:00:00

pages

15-20

issue

2 Suppl 2

eissn

0037-1963

issn

1532-8686

pii

S0037196303000702

journal_volume

40

pub_type

杂志文章,评审
  • Myelodysplastic syndromes: From pathogenesis and prognosis to treatment.

    abstract::Myelodysplastic syndromes (MDS) are clonal hematologic disorders characterized by ineffective hematopoiesis resulting in peripheral cytopenia and by increased progression to acute myelocytic leukemia (AML). With the exception of allogeneic stem cell transplantation, there is generally no curative treatment for these d...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminhematol.2004.02.002

    authors: Fenaux P

    更新日期:2004-04-01 00:00:00

  • Anemia of chronic disease.

    abstract::Anemia of chronic disease (ACD) or inflammation may be secondary to infections, autoimmune disorders, chronic renal failure, or malignancies. It is characterized by an immune activation with an increase in inflammatory cytokines and resultant increase in hepcidin levels. In addition, inappropriate erythropoietin level...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminhematol.2013.06.006

    authors: Gangat N,Wolanskyj AP

    更新日期:2013-07-01 00:00:00

  • Culture of hematopoietic stem cells purified from murine bone marrow.

    abstract::The results of the Y-chromosome in situ hybridization experiments, the MRA assessment, and the long-term production of CFU-GM in vitro indicate that our protocol to sort low density WGA+, 15/1.1-, Rh123 dull cells enriches about 200-fold for PHSC. Assays for spleen colony formation (CFU-S) and radioprotection (30-day ...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:

    authors: Visser JW,de Vries P,Hogeweg-Platenburg MG,Bayer J,Schoeters G,van den Heuvel R,Mulder DH

    更新日期:1991-04-01 00:00:00

  • A phase I study of idarubicin hydrochloride in patients with acute leukemia. The Idarubicin Study Group of Japan.

    abstract::This phase I trial of idarubicin (IDA) was conducted in 32 patients with acute leukemia and chronic myelogenous leukemia (CML) in blastic crisis (CML/BC) who either had failed to achieve a complete remission (CR) after initial induction therapy or had relapsed after CR. IDA was administered at dosages ranging from an ...

    journal_title:Seminars in hematology

    pub_type: 临床试验,杂志文章,评审

    doi:

    authors: Tamura K

    更新日期:1996-10-01 00:00:00

  • Management of the relapsed/refractory myeloma patient: strategies incorporating lenalidomide.

    abstract::The immunomodulatory drug (IMiD) lenalidomide is a more potent immunomodulator than thalidomide with respect to its effects on cytokine modulation and increased T-cell proliferation. Of all the IMiDs, clinical trial data are most mature for lenalidomide. In phase I studies, dose-limiting toxicities of lenalidomide wer...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminhematol.2005.10.004

    authors: Richardson P

    更新日期:2005-10-01 00:00:00

  • Clinical implications of recurring chromosomal and associated molecular abnormalities in acute lymphoblastic leukemia.

    abstract::Comprehensive study of the major chromosomal/molecular abnormalities in children and adults with acute lymphoblastic leukemia (ALL) has demonstrated prognostic utility for many of these anomalies, to the extent that cytogenetic and molecular genetic evaluations are now required for optimal clinical management of newly...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1016/s0037-1963(00)90018-0

    authors: Ferrando AA,Look AT

    更新日期:2000-10-01 00:00:00

  • Diagnosis and epidemiology of human herpesvirus 8 infection.

    abstract::There is consensus that human herpesvirus 8 (HHV-8) is a necessary, albeit not sufficient, causal agent of Kaposi's sarcoma (KS). In the past several years, there have been rapid advances in our understanding of HHV-8 infection. In diagnosis, antibody detection is more sensitive than nucleic acid-based techniques. Whi...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1053/shem.2003.50013

    authors: Martin JN

    更新日期:2003-04-01 00:00:00

  • Red cell enzymopathies of the glycolytic pathway.

    abstract::The delineation of specific erythrocyte glycolytic enzyme defects during the past three decades has clarified hitherto unexplained hereditary hemolytic syndromes. The glycolytic enzymopathies have proven to be important, not as a public health problem, but because the investigation of these experimental models of natu...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:

    authors: Tanaka KR,Zerez CR

    更新日期:1990-04-01 00:00:00

  • Improving the safety profile of warfarin.

    abstract::Since warfarin remains the predominate drug administered for long-term anticoagulation, optimizing therapy for maximum antithrombotic effect with minimal bleeding risk continues to challenge clinicians. Genetic differences exist that affect an individual's response to warfarin. The clinician can use genetic informatio...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1053/shem.2002.34089

    authors: Chai SJ,Macik BG

    更新日期:2002-07-01 00:00:00

  • Perspectives on familial chronic lymphocytic leukemia: genes and the environment.

    abstract::Chronic lymphocytic leukemia (CLL) comprises a substantial proportion of leukemias in adults in the western hemisphere. Male gender, increasing age, ethnicity (high in Caucasians, lowest in Asians), and family history are risk factors. Although no specific extrinsic etiologic factors have been established, farming and...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminhematol.2004.05.002

    authors: Caporaso N,Marti GE,Goldin L

    更新日期:2004-07-01 00:00:00

  • Risks and benefits of erythropoiesis-stimulating agents in cancer management.

    abstract::Anemia is frequently diagnosed in patients with cancer and its treatment is an important clinical problem. The deficiency in red blood cells (RBCs) can be a debilitating problem, and anemia correlates with poor performance status, deteriorates quality of life, and may negatively influence the prognosis of cancer patie...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminhematol.2007.04.004

    authors: Beutel G,Ganser A

    更新日期:2007-07-01 00:00:00

  • Activity survey and historical perspective of autologous stem cell transplantation in Europe.

    abstract::Autologous hematopoietic stem cell transplantation (HSCT) has a long tradition in Europe. Initially developed as a tool to restore rapid remission or chronic phase in patients with advanced leukemia without a sibling donor, it evolved over the last three decades to be used as a standard tool in patients with malignanc...

    journal_title:Seminars in hematology

    pub_type: 历史文章,杂志文章

    doi:10.1053/j.seminhematol.2007.09.001

    authors: Gratwohl A

    更新日期:2007-10-01 00:00:00

  • Resistance to imatinib: mutations and beyond.

    abstract::Mechanisms of resistance to the tyrosine kinase inhibitor (TKI) imatinib had been modeled in vitro even prior to the first reports of clinical resistance in patients with chronic myeloid leukemia (CML). The discovery that BCR-ABL is reactivated at the time of resistance and the unveiling of point mutations within the ...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminhematol.2010.06.005

    authors: La Rosée P,Deininger MW

    更新日期:2010-10-01 00:00:00

  • The virome in hematology-Stem cell transplantation and beyond.

    abstract::The virome has been recently studied in hematology and mostly in the setting of allogeneic hematopoietic stem cell transplantation. However, in hematology (as in the setting of nonhematological disorders) the study of the microbiome (that indeed includes the virome) is a growing field. The overall field is moving beyo...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminhematol.2020.05.001

    authors: Legoff J,Michonneau D,Socie G

    更新日期:2020-01-01 00:00:00

  • Control of late neutrophil-specific gene expression: insights into regulation of myeloid differentiation.

    abstract::During myeloid differentiation, the pluripotent hematopoietic stem cell passes through several well-defined morphologic stages within the bone marrow. These changes include progressive nuclear segmentation and the acquisition of stage-specific granules. Primary granules appear at the myeloblast stage, and are found in...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:

    authors: Sigurdsson F,Khanna-Gupta A,Lawson N,Berliner N

    更新日期:1997-10-01 00:00:00

  • Antibody-targeted therapy for myeloid leukemia.

    abstract::The availability of antibodies reactive with antigens expressed only by hematopoietic cells has provided clinical investigators with new tools for use in developing therapies for acute myeloid leukemia (AML). Studies performed to date have investigated the use of such antibodies in an unmodified state, combined with p...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:

    authors: Appelbaum FR

    更新日期:1999-10-01 00:00:00

  • Cellular hematopoiesis in the twentieth century.

    abstract::From work particularly In the last two decades of the century, the cell populations forming blood cells can now be purified and cultured clonally so that blood cell formation can be analyzed in vitro. A large number of specific regulators of this process have been identified and mass-produced in recombinant form. Thre...

    journal_title:Seminars in hematology

    pub_type: 历史文章,杂志文章,评审

    doi:

    authors: Metcalf D

    更新日期:1999-10-01 00:00:00

  • Monoclonal antibodies in lymphoma: the first decade.

    abstract::The past decade has seen improvements in overall survival (OS) for patients with the two most common lymphoma histologies: diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL). In FL, at least four independent datasets have confirmed these survival improvements. The monoclonal antibody rituximab has sign...

    journal_title:Seminars in hematology

    pub_type:

    doi:10.1053/j.seminhematol.2008.02.005

    authors: Link BK,Friedberg JW

    更新日期:2008-04-01 00:00:00

  • Farnesyltransferase inhibitors: novel compounds in development for the treatment of myeloid malignancies.

    abstract::The farnesyltransferase inhibitors (FTIs) have been shown in early clinical trials to elicit antitumor actions in a broad range of solid and hematologic malignancies. The mechanism of FTI action involves blockade of farnesyltransferase, an enzyme implicated in multiple cell-signaling pathways involved in proliferation...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1053/shem.2002.35984

    authors: Cortes JE,Kurzrock R,Kantarjian HM

    更新日期:2002-07-01 00:00:00

  • Non-Diamond Blackfan anemia disorders of ribosome function: Shwachman Diamond syndrome and 5q- syndrome.

    abstract::A number of human disorders, dubbed ribosomopathies, are linked to impaired ribosome biogenesis or function. These include but are not limited to Diamond Blackfan anemia (DBA), Shwachman Diamond syndrome (SDS), and the 5q- myelodysplastic syndrome (MDS). This review focuses on the latter two non-DBA disorders of ribos...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminhematol.2011.01.002

    authors: Burwick N,Shimamura A,Liu JM

    更新日期:2011-04-01 00:00:00

  • Immune dysregulation in immune thrombocytopenia.

    abstract::Immune thrombocytopenia (ITP) is a bleeding disorder characterized by low platelet counts due to decreased platelet production as well as increased platelet destruction by autoimmune mechanisms. A shift toward Th1 and possibly Th17 cells together with impaired regulatory compartment, including T-regulatory (Tregs) and...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminhematol.2013.03.011

    authors: Yazdanbakhsh K,Zhong H,Bao W

    更新日期:2013-01-01 00:00:00

  • Predictive genetic variants for venous thrombosis: what's new?

    abstract::Various pathways lead to the development of venous thrombosis. Risk factors are common and can be genetic or acquired. Since the identification of factor V Leiden and prothrombin 20210 G-->A, the field of genetic epidemiology has developed rapidly and many new genetic variants have been described in the past decade. H...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminhematol.2007.01.007

    authors: Bezemer ID,Rosendaal FR

    更新日期:2007-04-01 00:00:00

  • The manufacturing process for recombinant factor IX.

    abstract::Advances in recombinant DNA manufacturing technology have now made possible the production of a highly purified and active recombinant factor IX (rFIX) product. Recombinant factor IX was developed by (1) stable insertion of the genes for both factor IX and PACE-SOL (a truncated, soluble serine protease needed to enhan...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:

    authors: Harrison S,Adamson S,Bonam D,Brodeur S,Charlebois T,Clancy B,Costigan R,Drapeau D,Hamilton M,Hanley K,Kelley B,Knight A,Leonard M,McCarthy M,Oakes P,Sterl K,Switzer M,Walsh R,Foster W

    更新日期:1998-04-01 00:00:00

  • Hereditary spherocytosis--defects in proteins that connect the membrane skeleton to the lipid bilayer.

    abstract::The molecular causes of hereditary spherocytosis (HS) have been unraveled in the past decade. No frequent defect is found, and nearly every family has a unique mutation. In dominant HS, nonsense and frameshift mutations of ankyrin, band 3, and beta-spectrin predominate. Recessive HS is most often due to compound heter...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminhematol.2004.01.002

    authors: Eber S,Lux SE

    更新日期:2004-04-01 00:00:00

  • CD4+CD25+ regulatory T cells and graft-versus-host disease.

    abstract::Peripheral suppression of autoreactive T cells by specialized T-cell populations is one of several mechanisms ensuring self-tolerance within the adaptive immune system. Thymus-derived CD4+CD25+ T cells expressing the transcriptional repressor FOXP3 mediate such immunoregulatory functions and are pivotal for the preven...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminhematol.2005.09.006

    authors: Hoffmann P,Edinger M

    更新日期:2006-01-01 00:00:00

  • Targeted therapies in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia.

    abstract::Imatinib mesylate (Gleevec, Novartis Pharmaceuticals Corp, East Hanover, NJ; Glivec, Novartis Pharma AG, Basel, Switzerland), a signal transduction inhibitor with preferential effects against the tyrosine kinase activity of the protein product of the ABL proto-oncogene, induced hematologic responses in >or=90% of pati...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1053/shem.2002.36927

    authors: Hoelzer D,Gökbuget N,Ottmann OG

    更新日期:2002-10-01 00:00:00

  • New anti-thrombotic agents: emphasis on hemorrhagic complications and their management.

    abstract::Our advanced knowledge of coagulation has led to the synthesis of novel procoagulant substances, such as recombinant activated factor VII (rFVIIa; NovoSeven, Novo Nordisk, Bagsvaerd, Denmark). Similarly, in-depth understanding of the interaction between anticoagulant proteins and their natural inhibitors has led to th...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminhematol.2005.11.023

    authors: Ng HJ,Crowther MA

    更新日期:2006-01-01 00:00:00

  • Randomized trial experience of the Intergroupe Francophone du Myélome.

    abstract::This article summarizes clinical results of the Intergroupe Francophone du Myélome (IFM) trials: high-dose therapy (HDT) supported with autologous stem cells improves survival, melphalan 200 mg/m(2) is the best preparative regimen, unpurged peripheral blood stem cells (PBSC) are the recommended source of stem cells to...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1016/s0037-1963(01)90014-9

    authors: Attal M,Harousseau JL

    更新日期:2001-07-01 00:00:00

  • The Oklahoma Thrombotic Thrombocytopenic Purpura-Hemolytic Uremic Syndrome (TTP-HUS) Registry: a community perspective of patients with clinically diagnosed TTP-HUS.

    abstract::The Oklahoma Thrombotic Thrombocytopenic Purpura-Hemolytic Uremic Syndrome (TTP-HUS) Registry enrolls all consecutive patients for whom plasma exchange treatment is requested for clinically diagnosed TTP-HUS within a defined geographic region. During 14.5 years, from January 1, 1989 until June 30, 2003, 301 patients h...

    journal_title:Seminars in hematology

    pub_type: 杂志文章

    doi:10.1053/j.seminhematol.2003.10.001

    authors: George JN,Vesely SK,Terrell DR

    更新日期:2004-01-01 00:00:00

  • Experience of the Polycythemia Vera Study Group with essential thrombocythemia: a final report on diagnostic criteria, survival, and leukemic transition by treatment.

    abstract::This report suggests modest changes in the criteria used for the diagnosis of ET and allows tentative recommendations concerning therapy. As outlined in Table I, we believe that absent stainable marrow iron does not necessarily indicate iron deficiency in these patients and that the serum ferritin and RBC mean corpusc...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:

    authors: Murphy S,Peterson P,Iland H,Laszlo J

    更新日期:1997-01-01 00:00:00